The NPPA has directed strict monitoring of revised prices for 137 non-scheduled anti-cancer drugs under a 30 per cent trade margin cap. State Drug Controllers must ensure compliance, while estimated savings for patients from the price cuts stand at Rs 3,541 crore.
